HLC Members Commit Billions to Strengthen U.S. Healthcare Infrastructure for American Patients 

Note: this blog was originally published in May 2025 and has been updated as new announcements were made throughout the year. It was most recently updated November 6, 2025.

From drug makers and device manufacturers to care providers, HLC members are investing significantly in domestic facilities to ensure greater supply chain resilience, improve access to critical therapies, and strengthen the nation’s healthcare infrastructure.

These efforts have been recognized by President Trump and align with White House communications promoting domestic manufacturing.

HLC member companies understand the importance of expanding U.S. production of lifesaving medicines and devices. These investments will protect access to healthcare, increase jobs, and drive economic growth in communities, while keeping resources as local as possible for American patients. 

Investments To Expand Domestic Manufacturing, R&D, and Production 

Since the beginning of the year, many HLC member companies have announced major investments in new U.S.-based infrastructure.  

• In a landmark partnership with Eli Lilly and Company and Virginia higher education institutions, AstraZeneca and Merck have committed up to $120 million of private industry investment toward developing the Virginia Center for Advanced Pharmaceutical Manufacturing. This builds on over $12.5 billion in recently announced capital investment from the Life Sciences sector, committing to create thousands of jobs in the Commonwealth, as well as other U.S.-based investments by the companies, including:
  • In May, AstraZeneca opened a new $300 million cell therapy manufacturing site in Maryland.
    • This facility represents a portion of the company’s planned investments to expand its research and manufacturing footprint in the U.S., with $3.5 billion of capital investment by the end of 2026.
  • In October, Merck announced the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. There are also plans to invest $3 billion in biologics and small molecule manufacturing sites and capabilities in the U.S., which is expected to create more than 800 jobs, while also investing more than $3.5 billion in its Rahway, N.J. headquarters, which is expected to create roughly 1,000 jobs across research and clinical manufacturing.
    • In March, the company announced plans to expand U.S. manufacturing through a $1 billion investment at its Durham, North Carolina, site.
    • Just weeks later, the company began construction on a $1 billion biologics center of excellence in Delaware.
• This fall, Amgen announced multiple U.S. investments, including plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California and a $650 million expansion at the company’s biologics manufacturing facility in Juncos.
  • These latest investments build on several other major facility projects, including increasing its manufacturing capacity in Ohio with a $900 million facility.
  • Following a December 2024 announcement of a $1 billion investment in a second North Carolina manufacturing facility, Amgen also held a January ribbon-cutting ceremony for an advanced drug substance facility that totaled its Holly Springs investments to $1.5 billion.
• Ferring Pharmaceuticals received approval in April from the Food and Drug Administration for a state-of-the-art drug manufacturing hub in New Jersey, which secures a final $200 million payment from Royalty Pharma (Nasdaq: RPRX) as part of a royalty-based financing agreement announced in 2023.
• In late March, Johnson & Johnson (J&J) committed to increase their U.S. investment by more than $55 billion over the next four years.
  • The company has already broken ground on a new cutting-edge biologics facility in North Carolina.
• In April, Novartis announced it will expand its U.S.-based manufacturing and research and development (R&D) footprint with a more than $23 billion investment over the next five years.

All these initiatives will importantly create thousands of new American jobs and positively contribute to the U.S. economy. 

Investments to Create New Care Sites for American Patients 

Beyond manufacturing and R&D facilities, HLC member companies are also expanding sites-of-care to increase treatment access for patients. 

• AdventHealth has invested in many new facilities already this year. It has unveiled:
  • The plans for a transformation of its AdventHealth Orlando campus, with more than $1 billion investments announced in May.
  • A $300 million expansion project at AdventHealth Parker in Colorado;
  • Expanded sites in Missouri, and in Florida in St. Johns County, Ocala, and south Orange County;
  • Plans to invest $81 million toward building a medical campus in The Aurora Highlands in Colorado;
  • A newly renovated $2.5 million, state-of-the-art Cath lab in Florida;
  • Construction on the $43.2 million AdventHealth Cancer Institute at Winter Garden in Florida.
• Announced in March, Advocate Health plans to make a nearly $50 million investment in a health and wellness center in Milwaukee, Wisconsin.
  • The company also unveiled the launch of the first U.S. health system to provide hospital-level medical services at home for both pediatric and adult patients.
• In May, Ascension Saint Thomas shared plans for a new $148.5 million hospital and health campus in Tennessee.
• City of Hope has recently opened two new cancer centers. In April, it unveiled a new facility at One Scottsdale Medical in Arizona. A month later, the company launched the $400 million Hope Plaza in Los Angeles, California, the largest outpatient cancer center in its national system.
• Following its Bold.Forward.Unbound. model announcement, Mayo Clinic shared plans in March and April for hospital and clinic expansions across multiple states, including a $1.9 billion investment in Arizona, a new Mayo Clinic care facility in Minnesota, and a five-floor patient tower expansion in Florida.
• In August 2024, Texas Health Resources shared plans for a new, full-service hospital and on-campus medical office in Kaufman County, Texas.

Investments to Enhance Medical Product Deliveries and Emerging Technologies Facilities 

The distribution facilities that enable smooth and safe deliveries of medical products are also being bolstered by HLC member companies.

• Last year, AdventHealth celebrated its new Consolidated Service Center serving more than 125,000 patients in Florida. 
• Announced in January, Cardinal Health has since opened a new 340,000 square foot distribution center in Texas, to increase inventory capacity. This facility marks the third distribution center built in the past three years. The company has plans to further expand at-Home solutions operations with a new facility in California.
  • It also recently shared plans to build a 230,000 square-foot pharmaceutical plant in Indianapolis.
  • Cardinal Health also unveiled their new Consumer Health Logistics Center in Ohio in September.
• In November, Cencora shared plans to invest $1 billion through 2030 to bolster and expand its U.S. pharmaceutical distribution network.
• McKesson also expanded its Ohio presence, with McKesson Medical-Surgical opening a new distribution center.
• In February, Labcorp added 110,000 square feet of laboratory space and a state-of-the-art warehouse and logistics hub in New Jersey.

With a focus on advancing healthcare through innovative artificial intelligence (AI) tools and technologies, Mount Sinai Health System opened the Hamilton and Amabel James Center for Artificial Intelligence and Human Health in New York late last year.  

The healthcare system is made up of many sectors that provide innovative, lifesaving care to patients. As the industry invests in opportunities to improve access, this domestic growth plays a crucial role in bringing medical services closer to Americans.